Atherosclerotic disease and management challenges with nanomedicine: EU FP7 NMP funded “NanoAthero” and “CosmoPHOS-nano” large-scale projects
1Inserm, U1148, LVTS, X Bichat Hospital, University Paris Diderot, University Paris Nord, 46 rue H Huchard, 75018 Paris, France
2CosmoPHOS Ltd (European SME for Translational Nanomedicine), 77 Tsimiski Street, GR-54622, Thessaloniki, Greece (Ellas)
Cite as: Didier Letourneur, Panagiotis N. Trohopoulos. Atherosclerotic disease and management challenges with nanomedicine: EU FP7 NMP funded “NanoAthero” and “CosmoPHOS-nano” large-scale projects, nano Online. (2016). DOI: https://doi.org/10.1515/nano.0012.00060
Cite as: Didier Letourneur, Panagiotis N. Trohopoulos. Atherosclerotic disease and management challenges with nanomedicine: EU FP7 NMP funded “NanoAthero” and “CosmoPHOS-nano” large-scale projects, European Journal of Nanomedicine. 6, 115 (2014). DOI: https://doi.org/10.1515/ejnm-2014-0010
Abstract
Atherosclerosis is the most important arterial wall disease that causes arterial stenosis and may lead to the clinical manifestations of angina, heart attack and stroke. There is a demanding unmet medical need for new approaches for early diagnosis and improved/novel targeted therapies and therapy monitoring of atherosclerosis. This is the focus of two European large scale projects, the NanoAthero and the CosmoPHOS-nano by using nanomedicine. The aim is to demonstrate that nanotechnology-enabled systems can be successfully developed and clinically proven to be safe and effective in tackling cardiovascular diseases.
Keywords: atherosclerosis; imaging; nanomedicine; theranostics; therapy; translation
